In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

A Lesson From Tecentriq’s Development

Executive Summary

Roche chose not to limit enrollment to patients with high levels of PD-L1 expression when it moved Tecentriq into Phase II – unlike Merck, which did not include low PD-L1 expressers in its Keytruda lung cancer trials.

Advertisement

Related Content

How Immuno-Oncology Is Turning Biomarker Development On Its Head
Roche: OAK Data Differentiates Tecentriq In Second-Line Lung Cancer

Topics

Related Companies

UsernamePublicRestriction

Register